What Has Been The Evolution of the Growth Hormone Deficiency Market in Recent Years?
The growth hormone deficiency market has seen considerable growth due to a variety of factors.
• The market size for growth hormone deficiency has seen substantial growth in the past few years. It's projected to rise from $4.06 billion in 2024 to $4.31 billion in 2025, marking a compound annual growth rate (CAGR) of 6.1%.
Factors such as a surge in strategic initiatives, a growing rate of brain tumor incidences, amplified demand for hormone therapies, an aging population, and increased government healthcare funding are responsible for the market's historical growth.
What Is the Forecasted Market Size and Growth Rate for The Growth Hormone Deficiency Market Size In The Coming Years?
The growth hormone deficiency market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market size of growth hormone deficiency is predicted to experience robust growth. It is projected to escalate to $5.42 billion by 2029, with a compound annual growth rate (CAGR) of 5.9%.
The surge during the forecast period can be linked to the rising prevalence of genetic disorders, the escalation in strategic initiatives, boosted research and development, intensifying morbidity of Gh disease, and an increasing tally of clinical trials. The forecast period will see major trends such as technological evolution, expansion of treatment options, advancements in diagnostic methods, new and recent developments, and progress in biotechnology.
What Factors Are Driving Growth In The Growth Hormone Deficiency Market?
The increasing frequency of genetic disorders is set to drive the expansion of the growth hormone deficiency market. Genetic disorders are medical conditions triggered by irregularities or mutations in a person's DNA, either inherited or spontaneously occurring. Advancements in diagnostic technology, heightened awareness, an increase in maternal age, environmental factors causing mutations, population growth, and better survival rates for affected individuals all contribute to the prevalence of genetic disorders. Growth hormone deficiency is deployed to manage growth-related issues in certain genetic situations. For instance, a report issued by the Department of Health & Social Care (DHSC), a government department based in the UK, revealed that in October 2022 roughly 33,000 full genome equivalents were sequenced, resulting in an average diagnostic yield of 32%, which rose to 61% in certain conditions. Thus, the rising occurrence of genetic disorders propels the expansion of the growth hormone deficiency market.
What Are The Main Segments Of The Global Growth Hormone Deficiency Market?
The growth hormone deficiency market covered in this report is segmented –
1) By Type: Pediatric Growth Hormone Deficiency, Adult Growth Hormone Deficiency
2) By Treatment: Pharmacological Therapy, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts, Surgery
3) By Route Of Administration: Intravenous, Intramuscular, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Pediatric Growth Hormone Deficiency: Idiopathic Growth Hormone Deficiency, Genetic Growth Hormone Deficiency, Acquired Growth Hormone Deficiency
2) By Adult Growth Hormone Deficiency: Primary Growth Hormone Deficiency, Secondary Growth Hormone Deficiency
Pre-Book The Growth Hormone Deficiency Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Growth Hormone Deficiency Market?
The growth hormone deficiency market is witnessing a focus on innovation from key players, with efforts centered on the development of new products, such as unmodified somatropin, for routine pediatric growth hormone deficiency (GHD) treatments. Unmodified somatropin is the typical growth hormone used in daily pediatric GHD treatments, but with Skytrofa, it's delivered as a once-weekly dosage. In September 2023, the SKYTROFA (lonapegsomatropin) product was launched by Ascendis Pharma A/S, a biopharmaceutical company based in Denmark, as the first once-weekly treatment for pediatric GHD. This innovative treatment stands out for its enhanced convenience, superior adherence, and the possibility of improved treatment outcomes compared to regular daily growth hormone therapies. Moreover, it's the only FDA-approved once-weekly treatment for pediatric GHD, setting it apart as a milestone in the field of endocrinology and pediatric care.
Who Are the Key Players In The Growth Hormone Deficiency Market?
Major companies operating in the growth hormone deficiency market are:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• AbbVie Inc.
• Eli Lilly and Company
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Genentech Inc.
• Ipsen Biopharmaceuticals Inc.
• Opko Health Inc.
• JCR Pharmaceuticals Co. Ltd.
• Ferring Pharmaceuticals Inc.
• Ascendis Pharma A/S
• Rani Therapeutics Inc.
• AnkeBio Co. Ltd.
• Aeterna Zentaris Inc.
• Zhongshan Sinobioway Hygene Biomedicine Co. Ltd.
• Versartis Inc.
• I-Mab Biopharma Co. Ltd.
What Is The Most Dominant Region In The Growth Hormone Deficiency Market?
North America was the largest region in the growth hormone deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the growth hormone deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
